Atrasentan hydrochlorideProduct ingredient for Atrasentan
- Name
- Atrasentan hydrochloride
- Drug Entry
- Atrasentan
Atrasentan is a novel, selective endothelin A receptor antagonist (SERA).3
In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist to be approved for this condition.3,4
- Accession Number
- DBSALT001999
- Structure
Structure for Atrasentan hydrochloride (DBSALT001999)
- Synonyms
- Atrasentan HCl / Atrasentan Hydrochloride